Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

First-in-human, randomized, double-blind clinical trial of differentially adjuvanted PAMVAC, a vaccine candidate to prevent pregnancy-associated malaria.

Mordmüller B, Sulyok M, Egger-Adam D, Resende M, de Jongh WA, Jensen MH, Smedegaard HH, Ditlev SB, Soegaard M, Poulsen L, Dyring C, Calle CL, Knoblich A, Ibáñez J, Esen M, Deloron P, Ndam N, Issifou S, Houard S, Howard RF, Reed SG, Leroy O, Luty AJF, Theander TG, Kremsner PG, Salanti A, Nielsen MA.

Clin Infect Dis. 2019 Jan 10. doi: 10.1093/cid/ciy1140. [Epub ahead of print]

PMID:
30629148
2.

Fighting Cancer Using an Oncofetal Glycosaminoglycan-Binding Protein from Malaria Parasites.

Agerbæk MØ, Bang-Christensen S, Salanti A.

Trends Parasitol. 2018 Dec 11. pii: S1471-4922(18)30242-3. doi: 10.1016/j.pt.2018.11.004. [Epub ahead of print]

PMID:
30551869
3.

Cross-Species Immune Recognition Between Plasmodium vivax Duffy Binding Protein Antibodies and the Plasmodium falciparum Surface Antigen VAR2CSA.

Gnidehou S, Mitran CJ, Arango E, Banman S, Mena A, Medawar E, Lima BAS, Doritchamou J, Rajwani J, Jin A, Gavina K, Ntumngia F, Duffy P, Narum D, Ndam NT, Nielsen MA, Salanti A, Kano FS, Carvalho LH, Adams JH, Maestre A, Good MF, Yanow SK.

J Infect Dis. 2019 Jan 1;219(1):110-120. doi: 10.1093/infdis/jiy467.

PMID:
30534974
4.

The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAM-independent manner.

Agerbæk MØ, Bang-Christensen SR, Yang MH, Clausen TM, Pereira MA, Sharma S, Ditlev SB, Nielsen MA, Choudhary S, Gustavsson T, Sorensen PH, Meyer T, Propper D, Shamash J, Theander TG, Aicher A, Daugaard M, Heeschen C, Salanti A.

Nat Commun. 2018 Aug 16;9(1):3279. doi: 10.1038/s41467-018-05793-2.

5.

The GAGOme: a cell-based library of displayed glycosaminoglycans.

Chen YH, Narimatsu Y, Clausen TM, Gomes C, Karlsson R, Steentoft C, Spliid CB, Gustavsson T, Salanti A, Persson A, Malmström A, Willén D, Ellervik U, Bennett EP, Mao Y, Clausen H, Yang Z.

Nat Methods. 2018 Nov;15(11):881-888. doi: 10.1038/s41592-018-0086-z. Epub 2018 Aug 13.

PMID:
30104636
6.

Correction for Gavina et al., "Clinical Outcomes of Submicroscopic Infections and Correlates of Protection of VAR2CSA Antibodies in a Longitudinal Study of Pregnant Women in Colombia".

Gavina K, Gnidehou S, Arango E, Hamel-Martineau C, Mitran C, Agudelo O, Lopez C, Karidio A, Banman S, Carmona-Fonseca J, Salanti A, Tuikue Ndam N, Hawkes M, Maestre A, Yanow SK.

Infect Immun. 2018 Jul 23;86(8). pii: e00366-18. doi: 10.1128/IAI.00366-18. Print 2018 Aug. No abstract available.

7.

Association of Antibodies to VAR2CSA and Merozoite Antigens with Pregnancy Outcomes in Women Living in Yaoundé, Cameroon.

Lloyd YM, Fang R, Bobbili N, Vanda K, Ngati E, Sanchez-Quintero MJ, Salanti A, Chen JJ, Leke RGF, Taylor DW.

Infect Immun. 2018 Aug 22;86(9). pii: e00166-18. doi: 10.1128/IAI.00166-18. Print 2018 Sep.

PMID:
29986889
8.

Persistent Plasmodium falciparum Infection in Women With an Intent to Become Pregnant as a Risk Factor for Pregnancy-associated Malaria.

Tuikue Ndam N, Tornyigah B, Dossou AY, Escriou G, Nielsen MA, Salanti A, Issifou S, Massougbodji A, Chippaux JP, Deloron P.

Clin Infect Dis. 2018 Nov 28;67(12):1890-1896. doi: 10.1093/cid/ciy380.

PMID:
29733338
9.

Virus-like particle display of HER2 induces potent anti-cancer responses.

Palladini A, Thrane S, Janitzek CM, Pihl J, Clemmensen SB, de Jongh WA, Clausen TM, Nicoletti G, Landuzzi L, Penichet ML, Balboni T, Ianzano ML, Giusti V, Theander TG, Nielsen MA, Salanti A, Lollini PL, Nanni P, Sander AF.

Oncoimmunology. 2018 Jan 5;7(3):e1408749. doi: 10.1080/2162402X.2017.1408749. eCollection 2018.

10.

Clinical Outcomes of Submicroscopic Infections and Correlates of Protection of VAR2CSA Antibodies in a Longitudinal Study of Pregnant Women in Colombia.

Gavina K, Gnidehou S, Arango E, Hamel-Martineau C, Mitran C, Agudelo O, Lopez C, Karidio A, Banman S, Carmona-Fonseca J, Salanti A, Tuikue Ndam N, Hawkes M, Maestre A, Yanow SK.

Infect Immun. 2018 Mar 22;86(4). pii: e00797-17. doi: 10.1128/IAI.00797-17. Print 2018 Apr. Erratum in: Infect Immun. 2018 Jul 23;86(8):.

11.

A versatile, high through-put, bead-based phagocytosis assay for Plasmodium falciparum.

Lloyd YM, Ngati EP, Salanti A, Leke RGF, Taylor DW.

Sci Rep. 2017 Oct 31;7(1):14705. doi: 10.1038/s41598-017-13900-4.

12.

Plasmodium falciparum Infection Early in Pregnancy has Profound Consequences for Fetal Growth.

Schmiegelow C, Matondo S, Minja DTR, Resende M, Pehrson C, Nielsen BB, Olomi R, Nielsen MA, Deloron P, Salanti A, Lusingu J, Theander TG.

J Infect Dis. 2017 Dec 19;216(12):1601-1610. doi: 10.1093/infdis/jix530.

PMID:
29029247
13.

Statistical prediction of immunity to placental malaria based on multi-assay antibody data for malarial antigens.

Siriwardhana C, Fang R, Salanti A, Leke RGF, Bobbili N, Taylor DW, Chen JJ.

Malar J. 2017 Sep 29;16(1):391. doi: 10.1186/s12936-017-2041-3.

14.

Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display.

Singh SK, Thrane S, Janitzek CM, Nielsen MA, Theander TG, Theisen M, Salanti A, Sander AF.

Vaccine. 2017 Jun 27;35(30):3726-3732. doi: 10.1016/j.vaccine.2017.05.054. Epub 2017 May 31.

PMID:
28578824
15.

Rainbow trout (Oncorhynchus mykiss) immune response towards a recombinant vaccine targeting the parasitic ciliate Ichthyophthirius multifiliis.

von Gersdorff Jørgensen L, Kania PW, Rasmussen KJ, Mattsson AH, Schmidt J, Al-Jubury A, Sander A, Salanti A, Buchmann K.

J Fish Dis. 2017 Dec;40(12):1815-1821. doi: 10.1111/jfd.12653. Epub 2017 May 26.

PMID:
28548690
16.

Clinical development of a VAR2CSA-based placental malaria vaccine PAMVAC: Quantifying vaccine antigen-specific memory B & T cell activity in Beninese primigravidae.

Gbédandé K, Fievet N, Viwami F, Ezinmegnon S, Issifou S, Chippaux JP, Dossou Y, Moutairou K, Massougbodji A, Ndam N, de Jongh WA, Søgaard TMM, Salanti A, Nielsen MA, Esen M, Mordmüller B, Deloron P, Luty AJF; Multi-centre research paper.

Vaccine. 2017 Jun 14;35(27):3474-3481. doi: 10.1016/j.vaccine.2017.05.027. Epub 2017 May 17.

PMID:
28527688
17.

Chemical characterisation of the whole plant cell wall of archaeological wood: an integrated approach.

Zoia L, Tamburini D, Orlandi M, Łucejko JJ, Salanti A, Tolppa EL, Modugno F, Colombini MP.

Anal Bioanal Chem. 2017 Jul;409(17):4233-4245. doi: 10.1007/s00216-017-0378-7. Epub 2017 May 8.

PMID:
28484806
18.

Pre-clinical and clinical development of the first placental malaria vaccine.

Pehrson C, Salanti A, Theander TG, Nielsen MA.

Expert Rev Vaccines. 2017 Jun;16(6):613-624. doi: 10.1080/14760584.2017.1322512. Epub 2017 Apr 28. Review.

PMID:
28434376
19.

An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.

Seiler R, Oo HZ, Tortora D, Clausen TM, Wang CK, Kumar G, Pereira MA, Ørum-Madsen MS, Agerbæk MØ, Gustavsson T, Nordmaj MA, Rich JR, Lallous N, Fazli L, Lee SS, Douglas J, Todenhöfer T, Esfandnia S, Battsogt D, Babcook JS, Al-Nakouzi N, Crabb SJ, Moskalev I, Kiss B, Davicioni E, Thalmann GN, Rennie PS, Black PC, Salanti A, Daugaard M.

Eur Urol. 2017 Jul;72(1):142-150. doi: 10.1016/j.eururo.2017.03.021. Epub 2017 Apr 10.

PMID:
28408175
20.

Novel adenovirus encoded virus-like particles displaying the placental malaria associated VAR2CSA antigen.

Andersson AC, Resende M, Salanti A, Nielsen MA, Holst PJ.

Vaccine. 2017 Feb 22;35(8):1140-1147. doi: 10.1016/j.vaccine.2017.01.016. Epub 2017 Jan 25.

PMID:
28131394
21.

Comparison of functional assays used in the clinical development of a placental malaria vaccine.

Pehrson C, Heno KK, Adams Y, Resende M, Mathiesen L, Soegaard M, de Jongh WA, Theander TG, Salanti A, Nielsen MA.

Vaccine. 2017 Jan 23;35(4):610-618. doi: 10.1016/j.vaccine.2016.12.028. Epub 2016 Dec 21.

22.

Burkitt lymphoma expresses oncofetal chondroitin sulfate without being a reservoir for placental malaria sequestration.

Agerbaek MØ, Pereira MA, Clausen TM, Pehrson C, Oo HZ, Spliid C, Rich JR, Fung V, Nkrumah F, Neequaye J, Biggar RJ, Reynolds SJ, Tosato G, Pullarkat ST, Ayers LW, Theander TG, Daugaard M, Bhatia K, Nielsen MA, Mbulaiteye SM, Salanti A.

Int J Cancer. 2017 Apr 1;140(7):1597-1608. doi: 10.1002/ijc.30575. Epub 2017 Feb 6.

23.

Erratum to: Molecular dissection of placental malaria protein VAR2CSA interaction with a chemo-enzymatically synthesized chondroitin sulfate library.

Sugiura N, Clausen TM, Shioiri T, Gustavsson T, Watanabe H, Salanti A.

Glycoconj J. 2016 Dec;33(6):995. No abstract available.

PMID:
27900573
24.

Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses.

Janitzek CM, Matondo S, Thrane S, Nielsen MA, Kavishe R, Mwakalinga SB, Theander TG, Salanti A, Sander AF.

Malar J. 2016 Nov 8;15(1):545.

25.

Antibody responses to the full-length VAR2CSA and its DBL domains in Cameroonian children and teenagers.

Fodjo BA, Atemnkeng N, Esemu L, Yuosembom EK, Quakyi IA, Tchinda VH, Smith J, Salanti A, Bigoga J, Taylor DW, Leke RG, Babakhanyan A.

Malar J. 2016 Nov 4;15(1):532.

26.

Oncofetal Chondroitin Sulfate Glycosaminoglycans Are Key Players in Integrin Signaling and Tumor Cell Motility.

Clausen TM, Pereira MA, Al Nakouzi N, Oo HZ, Agerbæk MØ, Lee S, Ørum-Madsen MS, Kristensen AR, El-Naggar A, Grandgenett PM, Grem JL, Hollingsworth MA, Holst PJ, Theander T, Sorensen PH, Daugaard M, Salanti A.

Mol Cancer Res. 2016 Dec;14(12):1288-1299. Epub 2016 Sep 21.

27.

Infections with Plasmodium falciparum during pregnancy affect VAR2CSA DBL-5 domain-specific T cell cytokine responses.

Gbédandé K, Cottrell G, Vianou B, Ibitokou S, Fernando A, Troye-Blomberg M, Salanti A, Moutairou K, Massougbodji A, Ndam NT, Deloron P, Luty AJ, Fievet N.

Malar J. 2016 Sep 21;15(1):485.

28.

Placental Sequestration of Plasmodium falciparum Malaria Parasites Is Mediated by the Interaction Between VAR2CSA and Chondroitin Sulfate A on Syndecan-1.

Ayres Pereira M, Mandel Clausen T, Pehrson C, Mao Y, Resende M, Daugaard M, Riis Kristensen A, Spliid C, Mathiesen L, E Knudsen L, Damm P, G Theander T, R Hansson S, A Nielsen M, Salanti A.

PLoS Pathog. 2016 Aug 24;12(8):e1005831. doi: 10.1371/journal.ppat.1005831. eCollection 2016 Aug.

29.

Real-time and label free determination of ligand binding-kinetics to primary cancer tissue specimens; a novel tool for the assessment of biomarker targeting.

Clausen TM, Pereira MA, Oo HZ, Resende M, Gustavson T, Mao Y, Sugiura N, Liew J, Fazli L, Theander TG, Daugaard M, Salanti A.

Sens Biosensing Res. 2016 Jul;9:23-30.

30.

Molecular dissection of placental malaria protein VAR2CSA interaction with a chemo-enzymatically synthesized chondroitin sulfate library.

Sugiura N, Clausen TM, Shioiri T, Gustavsson T, Watanabe H, Salanti A.

Glycoconj J. 2016 Dec;33(6):985-994. Epub 2016 Jun 10. Erratum in: Glycoconj J. 2016 Dec;33(6):995.

PMID:
27287227
31.

Adhesion of Plasmodium falciparum infected erythrocytes in ex vivo perfused placental tissue: a novel model of placental malaria.

Pehrson C, Mathiesen L, Heno KK, Salanti A, Resende M, Dzikowski R, Damm P, Hansson SR, King CL, Schneider H, Wang CW, Lavstsen T, Theander TG, Knudsen LE, Nielsen MA.

Malar J. 2016 May 26;15(1):292. doi: 10.1186/s12936-016-1342-2.

32.

Bacterial superglue enables easy development of efficient virus-like particle based vaccines.

Thrane S, Janitzek CM, Matondo S, Resende M, Gustavsson T, de Jongh WA, Clemmensen S, Roeffen W, van de Vegte-Bolmer M, van Gemert GJ, Sauerwein R, Schiller JT, Nielsen MA, Theander TG, Salanti A, Sander AF.

J Nanobiotechnology. 2016 Apr 27;14:30. doi: 10.1186/s12951-016-0181-1.

33.

Sphingoid esters from the molecular distillation of squid oil: A preliminary bioactivity determination.

Saliu F, Longhin E, Salanti A, Degano I, Della Pergola R.

Food Chem. 2016 Jun 15;201:23-8. doi: 10.1016/j.foodchem.2016.01.056. Epub 2016 Jan 14.

PMID:
26868543
34.

Influence of Intermittent Preventive Treatment on Antibodies to VAR2CSA in Pregnant Cameroonian Women.

Babakhanyan A, Tutterrow YL, Bobbili N, Salanti A, Wey A, Fogako J, Leke RJ, Leke RG, Taylor DW.

Am J Trop Med Hyg. 2016 Mar;94(3):640-9. doi: 10.4269/ajtmh.15-0521. Epub 2015 Dec 28.

35.

Comparison of the specificity of antibodies to VAR2CSA in Cameroonian multigravidae with and without placental malaria: a retrospective case-control study.

Babakhanyan A, Fang R, Wey A, Salanti A, Sama G, Efundem C, Leke RJ, Chen JJ, Leke RG, Taylor DW.

Malar J. 2015 Dec 1;14:480. doi: 10.1186/s12936-015-1023-6.

36.

A Novel Virus-Like Particle Based Vaccine Platform Displaying the Placental Malaria Antigen VAR2CSA.

Thrane S, Janitzek CM, Agerbæk MØ, Ditlev SB, Resende M, Nielsen MA, Theander TG, Salanti A, Sander AF.

PLoS One. 2015 Nov 23;10(11):e0143071. doi: 10.1371/journal.pone.0143071. eCollection 2015.

37.

Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein.

Salanti A, Clausen TM, Agerbæk MØ, Al Nakouzi N, Dahlbäck M, Oo HZ, Lee S, Gustavsson T, Rich JR, Hedberg BJ, Mao Y, Barington L, Pereira MA, LoBello J, Endo M, Fazli L, Soden J, Wang CK, Sander AF, Dagil R, Thrane S, Holst PJ, Meng L, Favero F, Weiss GJ, Nielsen MA, Freeth J, Nielsen TO, Zaia J, Tran NL, Trent J, Babcook JS, Theander TG, Sorensen PH, Daugaard M.

Cancer Cell. 2015 Oct 12;28(4):500-514. doi: 10.1016/j.ccell.2015.09.003.

38.

High-Throughput Testing of Antibody-Dependent Binding Inhibition of Placental Malaria Parasites.

Nielsen MA, Salanti A.

Methods Mol Biol. 2015;1325:241-53. doi: 10.1007/978-1-4939-2815-6_20.

PMID:
26450394
39.

Identification of a Major Dimorphic Region in the Functionally Critical N-Terminal ID1 Domain of VAR2CSA.

Doritchamou J, Sabbagh A, Jespersen JS, Renard E, Salanti A, Nielsen MA, Deloron P, Tuikue Ndam N.

PLoS One. 2015 Sep 22;10(9):e0137695. doi: 10.1371/journal.pone.0137695. eCollection 2015.

40.

The Influence of Sub-Unit Composition and Expression System on the Functional Antibody Response in the Development of a VAR2CSA Based Plasmodium falciparum Placental Malaria Vaccine.

Nielsen MA, Resende M, de Jongh WA, Ditlev SB, Mordmüller B, Houard S, Ndam NT, Agerbæk MØ, Hamborg M, Massougbodji A, Issifou S, Strøbæk A, Poulsen L, Leroy O, Kremsner PG, Chippaux JP, Luty AJ, Deloron P, Theander TG, Dyring C, Salanti A.

PLoS One. 2015 Sep 1;10(9):e0135406. doi: 10.1371/journal.pone.0135406. eCollection 2015.

41.

Protective Antibodies against Placental Malaria and Poor Outcomes during Pregnancy, Benin.

Ndam NT, Denoeud-Ndam L, Doritchamou J, Viwami F, Salanti A, Nielsen MA, Fievet N, Massougbodji A, Luty AJ, Deloron P.

Emerg Infect Dis. 2015 May;21(5):813-23. doi: 10.3201/eid2105.141626.

42.

Cytoadhesion of Plasmodium falciparum-infected erythrocytes to chondroitin-4-sulfate is cooperative and shear enhanced.

Rieger H, Yoshikawa HY, Quadt K, Nielsen MA, Sanchez CP, Salanti A, Tanaka M, Lanzer M.

Blood. 2015 Jan 8;125(2):383-91. doi: 10.1182/blood-2014-03-561019. Epub 2014 Oct 28.

43.

Targeted disruption of a ring-infected erythrocyte surface antigen (RESA)-like export protein gene in Plasmodium falciparum confers stable chondroitin 4-sulfate cytoadherence capacity.

Goel S, Muthusamy A, Miao J, Cui L, Salanti A, Winzeler EA, Gowda DC.

J Biol Chem. 2014 Dec 5;289(49):34408-21. doi: 10.1074/jbc.M114.615393. Epub 2014 Oct 23.

44.

The antibody response of pregnant Cameroonian women to VAR2CSA ID1-ID2a, a small recombinant protein containing the CSA-binding site.

Babakhanyan A, Leke RG, Salanti A, Bobbili N, Gwanmesia P, Leke RJ, Quakyi IA, Chen JJ, Taylor DW.

PLoS One. 2014 Feb 4;9(2):e88173. doi: 10.1371/journal.pone.0088173. eCollection 2014.

45.

Utilizing nanobody technology to target non-immunodominant domains of VAR2CSA.

Ditlev SB, Florea R, Nielsen MA, Theander TG, Magez S, Boeuf P, Salanti A.

PLoS One. 2014 Jan 21;9(1):e84981. doi: 10.1371/journal.pone.0084981. eCollection 2014.

46.

DNA secondary structures are associated with recombination in major Plasmodium falciparum variable surface antigen gene families.

Sander AF, Lavstsen T, Rask TS, Lisby M, Salanti A, Fordyce SL, Jespersen JS, Carter R, Deitsch KW, Theander TG, Pedersen AG, Arnot DE.

Nucleic Acids Res. 2014 Feb;42(4):2270-81. doi: 10.1093/nar/gkt1174. Epub 2013 Nov 18.

47.

Characterization of human placental glycosaminoglycans and regional binding to VAR2CSA in malaria infected erythrocytes.

Beaudet JM, Mansur L, Joo EJ, Kamhi E, Yang B, Clausen TM, Salanti A, Zhang F, Linhardt RJ.

Glycoconj J. 2014 Feb;31(2):109-16. doi: 10.1007/s10719-013-9506-6. Epub 2013 Oct 25.

48.

Plasmodium falciparum mutant haplotype infection during pregnancy associated with reduced birthweight, Tanzania.

Minja DT, Schmiegelow C, Mmbando B, Boström S, Oesterholt M, Magistrado P, Pehrson C, John D, Salanti A, Luty AJ, Lemnge M, Theander T, Lusingu J, Alifrangis M.

Emerg Infect Dis. 2013;19(9). doi: 10.3201/eid1909.130133.

49.

Differential adhesion-inhibitory patterns of antibodies raised against two major variants of the NTS-DBL2X region of VAR2CSA.

Doritchamou J, Bigey P, Nielsen MA, Gnidehou S, Ezinmegnon S, Burgain A, Massougbodji A, Deloron P, Salanti A, Ndam NT.

Vaccine. 2013 Sep 23;31(41):4516-22. doi: 10.1016/j.vaccine.2013.07.072. Epub 2013 Aug 9.

50.

Analysis of antibodies to newly described Plasmodium falciparum merozoite antigens supports MSPDBL2 as a predicted target of naturally acquired immunity.

Tetteh KK, Osier FH, Salanti A, Kamuyu G, Drought L, Failly M, Martin C, Marsh K, Conway DJ.

Infect Immun. 2013 Oct;81(10):3835-42. doi: 10.1128/IAI.00301-13. Epub 2013 Jul 29.

Supplemental Content

Loading ...
Support Center